Ogiwara et al. [54] conducted a drug sensitivity screening using ARID1A wild-type and ARID1A knockout HCT 116 colon cancer cells to determine the selectivity of GSH metabolic factor inhibitors for ARIDIA-deficient cancers. Here, ARID1A is linked to colonic neoplasm.